Shares of FibroGen Inc. (NASDAQ:FGEN) shot up 2.6% during trading on Monday . The company traded as high as $19.95 and last traded at $19.63, with a volume of 146,432 shares changing hands. The stock had previously closed at $19.13.

FGEN has been the topic of a number of analyst reports. Credit Suisse Group AG reiterated a “buy” rating on shares of FibroGen in a research report on Wednesday, May 25th. Zacks Investment Research upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $33.50.

The firm’s market cap is $1.23 billion. The firm has a 50-day moving average of $16.95 and a 200-day moving average of $18.52.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.11. Analysts predict that FibroGen Inc. will post ($1.02) EPS for the current fiscal year.

In other news, CEO Thomas B. Neff sold 37,798 shares of FibroGen stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $18.38, for a total transaction of $694,727.24. Following the transaction, the chief executive officer now owns 3,413,255 shares in the company, valued at $62,735,626.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas B. Neff sold 27,000 shares of FibroGen stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $16.02, for a total value of $432,540.00. Following the transaction, the chief executive officer now owns 3,439,764 shares in the company, valued at approximately $55,105,019.28. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have modified their holdings of the stock. Cornerstone Capital Management Holdings LLC. acquired a new position in shares of FibroGen during the fourth quarter worth $3,067,000. PNC Financial Services Group Inc. increased its position in shares of FibroGen by 8,621.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 35,756 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 35,346 shares in the last quarter. California Public Employees Retirement System acquired a new position in shares of FibroGen during the fourth quarter worth $3,397,000. Rhumbline Advisers increased its position in shares of FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 1,100 shares in the last quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.